RxDoctor Payments Data

Seth Mobley, DO

Family Medicine · Springdale, ARNPI 1891311254

Payments from drug & device makers

$2,181in general payments, 2019–2025

Across 114 payments — averaging $19.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$512
  • Bayer$194
  • Lilly USA, LLC$171
  • Astellas Pharma US Inc$157
  • Novo Nordisk$140
  • Pfizer$137
  • plus $869 from 16 others

What the payments were for

  • Food & beverage$2,181100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,181 in reported general payments places this provider in the 70th percentile of 1,347 family medicine providers in Arkansas.

See all family medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$26,353
Medicare patients
116
Services billed
515

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide17$20,045
Famotidine16$832
Atorvastatin Calcium67$822
Temazepam25$565
Losartan Potassium45$559
Albuterol Sulfate HfaAlbuterol Sulfate28$530
Pantoprazole Sodium45$455
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine16$448
Gabapentin26$411
Metoprolol Succinate19$348
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen28$337
Tamsulosin Hcl21$240
Levothyroxine Sodium21$236
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav22$227
Fluoxetine Hcl43$224

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$171$20,04517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,347 family medicine providers in Arkansas.

Other family medicine in Springdale

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →